Shifting emphasis from pharmacogenomics to theragnostics

被引：99

作者：

Ozdemir, Vural ^{[1
]}

Williams-Jones, Bryn

Glatt, Stephen J.

Tsuang, Ming T.

Lohr, James B.

Reist, Christopher

机构：

[1] So Calif Inst Res & Educ, Biomarker & Clin Pharmacol Unit, VA Long Beach Healthcare Syst, Irvine, CA USA

[2] Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA USA

[3] Mental Illness Res Educ & Clin Ctr, Long Beach, CA USA

[4] Mental Illness Res Educ & Clin Ctr, San Diego, CA USA

[5] Mental Illness Res Educ & Clin Ctr, Los Angeles, CA USA

[6] Univ Montreal, Grp Rech Bioeth, Montreal, PQ, Canada

[7] Univ Montreal, Dept Med Sociale & Prevent, Montreal, PQ, Canada

[8] Univ Calif San Diego, Ctr Behav Genom, San Diego, CA 92103 USA

[9] Univ Calif San Diego, Psychopharmacol Res Initiat Ctr Excellence, San Diego, CA 92103 USA

来源：

NATURE BIOTECHNOLOGY | 2006年 / 24卷 / 08期

关键词：

D O I：

10.1038/nbt0806-942

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

What will be the role of theragnostic patents in upstream and downstream biomarker research?

引用

页码：942 / 947

页数：6

共 38 条

[1] Pharmacogenomic-guided rational therapeutic drug monitoring: Conceptual framework and application platforms for atypical antipsychotics [J].

Albers, LJ ;

Ozdemir, V .

CURRENT MEDICINAL CHEMISTRY, 2004, 11 (03) :297-312

[2] Excess in the pharmaceutical industry [J].

Angell, M .

CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (12) :1451-1453

[3]

Baird P, 1998, PERSPECT BIOL MED, V41, P391

[4]

Brown N., 2003, SCI STUD, V16, P3, DOI DOI 10.23987/STS.55152

[5] Policy conflicts: Gene patents and health care in Canada [J].

Caulfield, T .

COMMUNITY GENETICS, 2005, 8 (04) :223-227

[6] Geneticists question fees for use of patented 'junk' DNA [J].

Dennis, C .

NATURE, 2003, 423 (6936) :105-105

[7] The price of innovation: new estimates of drug development costs [J].

DiMasi, JA ;

Hansen, RW ;

Grabowski, HG .

JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185

[8] Will pharmacogenomics alter the role of patents in drug development? [J].

Eisenberg, RS .

PHARMACOGENOMICS, 2002, 3 (05) :571-574

[9] The complexities of predictive genetic testing [J].

Evans, JP ;

Skrzynia, C ;

Burke, W .

BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7293) :1052-1056

[10] Drug therapy - Pharmacogenomics - Drug disposition, drug targets, and side effects [J].

Evans, WE ;

McLeod, HL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (06) :538-549

← 1 2 3 4 →